Sylvester Comprehensive Cancer Center

E-mail a Friend

Stephen P. Richman, M.D.

General Information

Stephen P. Richman, M.D.

Languages

  • English

Certifications

  • American Board of Internal Medicine
  • American Board of Internal Med-Medical Oncology

CV

Specialties

  • Internal Medicine
  • Hematology/Oncology - Internal Medicine

Roles

  • Professor of Medicine

Clinical Interests

Dr. Richman's clinical interests include clinical breast cancer care, clinical research, ethics and regulation.

Research Interests

Dr. Richman's research interests include breast cancer treatment and development of new anti-cancer agents.

Awards

Fellow
Junior Faculty Award
Member
Member

Education

1974 Fellowship
Department of Developmental Therapeutic M.D. Anderson Hospital and Tumor Institute
1972 Residency
Hospital University of Pennsylvania
1969 M.D.
Case Western Reserve University, School of Medicine
1965 B.A.
Washington University
1963 Undergraduate
Stanford University

Publications

  • 1.Richman, S.P., et al: Studies of Vicia faba root meristems irradiated with a negative pion beam. Rad. Res. Suppl. 7:283-289, l967.
  • 2. Izumi, A.K. and Richman, S.P.: Ectopic adrenocorticotropic hormone syndrome. Arch. Dermatol. l02:555-559, l970
  • 3. Richman, S.P., Mavligit, G.M., Wolk, R., Gutterman, J.U. and Hersh, E.M.: Epilesional scarification: Preliminary report on a new approach to local immunotherapy. JAMA 234:1233-1235, l975.
  • 4.Gercovich, F.G., Richman, S.P. Rodriguez, V., Luna, M., McCredie, K.B., and Brodey, G.P.Successful control of systemic Aspergillus niger infections in two patients with acute leukemia Cancer 36:2271-2276, l975
  • 5.Hersh, E.M., Gutterman, J.U., Mavligit, G.M., Reed, R.C., and Richman, S.P.: BCG vaccine and its derivatives.Potential practical considerations and precautions in human cancer immunotherapy. JAMA 235:646-650, l976.
  • 6.Richman,S.P.,Livingston, R.B., Gutterman, J.U., Suen, J.Y.and Hersh,E.M. Chemotherapy versus chemoimmunotherapy of head and neck cancer: Report of a randomizedstudy.Cancer Treat.Rep. 60:535-539, l976
  • Rodriguez, V., Richman, S.P., Benjamin, R.S., et al.: Phase II study with Baker's antifol in Solid tumors. Cancer Res. 37:980-983, l977.
  • Richman, S.P., Gutterman, J.U., Hersh, E.M. and Mavligit, G. M.: Phase I study of Immunotherapy with methanol extraction residue of BCG (MER).Cancer Treat. Repts. 6l: 47l-471, l977
  • Schwarz, M.A., Gutterman, J.U., Hersh, E.M., Richman, S.P. and Mavligit,G.M.Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions. World J Surg. l: 555-583, l977
  • Suen, J.Y., Richman, S.P., Livingston, R.L., Hersh, E.M., Craig, R. and Tonymon, KResults of the BCG adjuvant immunotherapy in l00 patients with epidermoid carcinoma of the head and neck. Am. J. Surg. l34:474-478, l977.
  • Hortobagyi, G.N., Richman, S.P. Dandridge, K., Gutterman, J.U., Blumenschein, D.R.andHersh, E.M.:Immunotherapy with BCG administration by scarification. Standardization of reactions and managements of side effects. Cancer 42:2293-2303, l978.
  • Hortobagyi, G.N., Gutterman, J.U., Snyder, R.O., Richman,S.P. and Hersh, E.M.Pseudomonas vaccine: A phase I evaluation for cancer research. Cancer Immunology and Immunotherapy 4:20l-207, l978.
  • Richman, S.P., Gutterman, J.U., Hersh, E.M. and Ribi, E.E.: Phase I-II study of intratumor immunotherapy with BCG cell wall skeleton plus P3. Cancer Immunology and Immunotherapy 5:4l-44, l978.
  • Issell, B.F., Valdevieso, M., Hersh, E.M., Richman, S.P., Gutterman, J.U. and Bodey, G.P Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer Treat Rep. 62:1059-1063, l978.
  • Richman, S.P., Gutterman,J.U. and Hersh, E.M.: Cancer Immunotherapy.Canadian Medical Assoc. J. 120:322-329, l979.
  • Hortobagyi, G.N., Gutterman, J.U., Blumenschein, G.R., Tashima, C.K., Burgess, M.A., Einhorn, L., Buzdar, A.U., Richman, S.P. and Hersh, E.M.: Combination chemotherapy of metastatic breast cancer with 5-fluorouracil, Adriamycin and Cyclophosphamide, BCG. Cancer 43:1225-1233, l979.
  • Blumenschein, G.R., Hortobagyi, G.N., Richman, S.P. et al: Alternating noncross resistant combination chemotherapy and active non-specific immunotherapy with BCG or MER-BCGfor advanced breast carcinoma. Cancer 45:742-749, l980.
  • Maroun, J.A., Quesada, J., Hersh, E.M., Gutterman, J.U., Richman, S.P. et al.: A phase I toxicity study of methanol extraction residue (MER) of Bacillus Calmette Guerin by intervenous route. Cancer Treat. Rep. 63:1781-1786, l979.
  • Richman, S.P., Gutterman, J.U. and Hersh, E.M.: Chemotherapy and Immunotherapy of malignant melanoma. Compreh. Ther. 6:57-6l, l980
  • Richman, S., Chism, V.T. and Murphy, S.G.: Effect of microbial fractions and vehicle on the survival of mice beating the Lewis lung carcinoma. Cancer Treat. Rep. 64:1329-1333, l980.
  • Richman, S.P., Hersh, E.M., Gutterman, J.U., Rios, A., Hortobagyi, G.N., Blumenschein, G.R.and Rib, E.E. Administration of BCG cell wall skeleton into malignant effusions. Toxic and therapeutic effects. Cancer Treat. Rep. 65:383-387, l98l.
  • Richman, S.P., Chism, V.T. and Murphy, S.G.: Augmentation of ADCC in mice by microbial fractions. Cancer Immunol. Immunother. 11:233-238, l981
  • Valdivieso, M., Richman, S., Burgess, A.M. et al.: Initial clinical studies of vindesine. Cancer Treat. Rep. 65:873-875, l98l.
  • Feun, L.G., Jordan, G., Burgess, M.A., Hersh, E.M., Mavligit, G., McBride, C.M., Benjamin, R.S. and Richman, S.P., et al.: The Natural History of Resectable Metastatic Melanoma (Stage IVA Melanoma). Cancer 50:1656-1663, l982.
  • Blijham, G.H., Barlogie, B. and Richman, S. Et al: Medulloblastoma and neuroblastoma in adults. Neth. J. Med. 25 (4):94-99, l982
  • Woodcock, T.M., Blumenreich, M.S., Richman, S.P. Kubota, T.T., Gentile, P.S. and Allegra, J.C.: Combination Chemotherapy with Cis-Diamminedichloroplatinum and Vinblastine in Advanced Non-Small Cell Lung Cancer. J. Clin. Oncology. l:247-250, l983.
  • Allegra, J.C., Woodcock, T.M., Richman, S.P., Bland, K.I. and Witliff, J.L.: A Phase II Trial of Tamoxifen, Premarin, Methotrexate and 5-Fluorouracil in Metastatic Breast Cancer. Breast Cancer Treat. and Res. 2:93-99, l982.
  • Richman, S.P., Woodcock, T. M., Kubota, T.T., Blumenreich, M.S., Gentile, P.S. and Allegra J.C.: A Phase II Trial of Vinblastine, Bleomycin and Cisplatin (VBP) Followed by Decarbazine and Mitolactol in Metastatic Melanoma. Cancer Treat. Repts. 68:l395-l396, l984.
  • Blumenreich, M.S.,Woodcock,T.M.,Jones, M., Richman, S.P. et al.:High-dose cisplatin diamminedichloroplatinum II in patients with advanced malignancies. Cancer 55:1118-1122, 1985.
  • Blumenreich, M.S., Woodcock, T.M., Richman, S.P, et al.: A Phase I trial of Dactinomycin intravenous infusion in patients with advanced malignancies. Cancer 56:256-258, l985.
  • Blumenreich, M.S., Woodcock, T.M., Gentile, P.S., Barnes, G.R., Jose, B., Sherrill, E.J., Richman, S.P., et al. High-Dose cisplatin and vinblastine infusion with or without radiation therapy in patients with advanced non-small cell lung cancer. J. Clin. Oncol. 5:l725-l730, l987.
  • Sridhar, K.S., Bounassi M.J., Raub, W., and Richman, S.P.: Clinical features of adenosquamous lung carcinoma in 127 patients. Am. Rev. Respir. Dis. 142:19-23, 1990.
  • Sridhar, K.S., Samy, T.S.A., Agarwal, R.P., Duncan, R.C., Benedetto, P., Krishan, A.G., Vogel, C.L., Feun, L.G., Savaraj,N.M., Richman,S.P. and Zubrod, C.G. A Phase I study of 4'-0-Tetrahydropyranyladriamycin. Cancer 66:2082-2091, 1990.
  • Feun, L.G., Savaraj, N., Benedetto, P., Hanlon, J., Sridhar, K.S., Collier, M., Richman, S., Liao, S.H., and Clendennin, N.J. Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies. J.Natl. Cancer Inst. 83: 51-55, 1991.
  • Ardalan, B, Chua, L., Tian, E., Reddy, R., Sridhar, K.S., Benedetto, P., Richman, S. et al. A Phase II study of weekly 24 hour infusion with high-dose Fluorouracil with Leucovorin in colorectal carcinoma. J. Clin Oncol 9: 625-630, l99l.
  • Sridhar, K., Hussein, A., Benedetto, P., Waldman, S., Feun, L., Savaraj, N., and Richman S. Phase II Trial of Mitoxantrone in Head and Neck Carcinoma. Am. J. Clin. Oncol. 14:298-304, 1991.
  • Ardalan, B., Sridhar K.S., Benedetto, P., Richman, S., Waldman, S., Morrell, L., Feun,L., Savaraj, N., Fodor, M., Livingstone, A. A Phase I, II Study of High Dose 5-Fluorouracil and High Dose Leucovorin with Low Dose Phosphonacetyl-L-Aspartic Acid in Patients with Advanced Malignancies. Cancer 68:1242-1246, 1991
  • Sridhar K.S., Raub, Jr., W., Duncan R.C., Hilsenbeck S., and Richman S.P. Lung carcinoma in 1,336 patients. Am. J. Clin. Oncol. 14:496-508, 1991
  • Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE, Siegel R and VandePol CJ. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J. Clin. Oncol. 10:134-142, 1992.
  • Ardalan, B., Sridhar, K., Reddy, R., Benedetto, P., Richman, S., Waldman, S., Morrell, L., Feun, L., Savaraj, N., and Livingstone, A. Phase I study of high dose 5-fluorouracil and high dose leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Int. J. Radiation Oncology Biol. Phys. 22: 511-514, 1992
  • Ardalan B., Ucar A., Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K. Phase I trial of low dose N-Phosphonacetyl-L-Aspartic Acid and High dose 5-Fluorouracil administered concomitantly with Radiation Therapy for Unresectable Localized Adenocarcinoma of the Pancreas. Cancer, 74:7, 1994.
  • Hantel, A., Tangen, C.M., Macdonald, J.S., Richman, S.P. et al. Phase II trial of trimetrexate in untreated advanced gastric carcinoma. Invest. New Drug 12:155-157, 1994.
  • Feun L.G., Savaraj, N., Moffat, F., Robinson, D., Liebmann, A., Hurley J., Raub, Jr.,W.A. and Richman, S.P. Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC, and tamoxifen in advanced malignant melanoma. Melanoma Res. 5: 273-276, 1995.
  • Whitehead R.P., Wolf, M.K., Solanski, D.L., Hemstreet, G.P., Benedetto, P., Richman, S.P. et al. A phase II trial of continuous infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: A Southwest Oncology Group Study. J. Immunotherapy 18: 104-114, 1995.
  • Martino, R.L., Fleming, T.R., Morrell, L.M., Ardalan,B., Richman, S.P., and Macdonald, J.S. Phase II trial of low dose N-(phosphonacetyl)-disodium-L-aspartic acid and high-dose 24-hour infusional 5-Fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group Study.Invest. New Drugs 14:419-421, 1996.
  • Morrell, L.E., Lee, Y.J., Hurley, J., Arias, M., Mies,C., Richman, S.P., Hernandez, H., Donofrio K., Raub, Jr.,W.A., and Cassileth, P.A. A phase II trial of neoadjuvant methotrexate, vinblastine,doxorubicin, and cisplatinum in the treatment of patients with locally advanced breast carcinoma. Cancer 82:503-511, 1998.
  • Anderson, K.O. Mendoza, T.R., Valero, V., Richman, S.P., et al. Minority Cancer Patients and their Providers. Pain management attitudes and practice. Cancer 88:1929-1938, 2000.
  • Anderson, K.O., Richman,S.P., Hurley, J., et. al. Cancer pain management among minority patients: Perceived needs and barriers to optimal control. Cancer 94: 2295-2304, 2002.
  • Anderson, K.O., Mendoza, T.R., Payne, R., Valero, V., Palos, G.R., Nazario,A., Richman,S.P.,et.al. Pai education for underserved minority cancer patients: A randomized controlled trial. J. Clini. Oncology. 22:4918 – 4925, 2004.
  • Cleveland, C.S., Mendoza, T.R., Wong, X.S., Woodruff, S.F., Palos, G.R., Richman, S.P., et.al. Level of symptom burden during chemotherapy for advanced lung cancer: Differences between public hospitals and a tertiary cancer center. In Press Journal of Clinical Oncology

Biography

Dr. Richman received his medical degree from Case-Western Reserve University and completed his medical residency at the University of Pennsylvania. He received his training in Oncology at the M.D. Anderson Hospital and Tumor Institute in Houston. He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.

E-mail a Friend